Surgical Science: Q4 2022, Sales growth in line, slightly softer margins than anticipated - Redeye

Redeye provides its initial take on Surgical Science’s Q4 2022 report, broadly aligning with our estimates. We judge that notable positives from the report include continued strong Educational Products sales growth and solid operating cash flow. Notable negatives include Industry/OEM sales slightly below our estimates and slightly softer margins than we had pencilled in.

Länk till analysen i sin helhet: https://www.redeye.se/research/882245/surgical-science-q4-2022-sales-growth-in-line-slightly-softer-margins-than-anticipated?utm_source=finwire&utm_medium=RSS